DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cataract 34 multiple types — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCataract 34 multiple types maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cataract 34 multiple types is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The Oxford Clinical Cataract Classification and Grading System was used to study associations between eleven lens features in 560 subjects from the Melton Eye Study. Within subjects, the two nuclear features, white nuclear scatter and brunescence, were closely related to one another, as were coronary flakes and focal-dots, but these two groupings were negatively associated. Cortical spoke, fibrefolds and waterclefts were all associated with one another, and this group was positively associated with coronary flakes and focal-dots. Posterior subcapsular and anterior subcapsular opacity were associated with one another and with cortical spokes. The authors concluded these associations may be important in defining cataract subtypes and in identifying minor features that indicate early cataract development.
A three-generation family with autosomal dominant congenital total cataract was studied to identify a causative mutation. Screening of the two reported genes CRYAA and GJA8, which are linked to human total cataracts, identified a novel mutation p.F32I in GJA8. The mutation codes for connexin 50 (Cx50). Plasmids carrying wild-type and mutant mouse Gja8 were expressed in 293 cells. Confocal microscopy showed that the molecular consequences of the p.F32I mutation exclude instability and mislocalisation of the mutant Cx50 protein. The study adds a novel mutation to the existing spectrum of Cx50 mutations with cataract.
A 2025 review states that cataracts remain the leading cause of blindness globally, and that oxidative stress is widely acknowledged as the primary influencing factor. The review notes that there are currently no drugs on the market capable of truly reversing cataracts; existing medications can only alleviate the progression of the condition to a certain extent. Surgical treatment remains the only effective approach at this stage, though economic limitations and the risks of postoperative complications hinder its accessibility for certain patient groups. The review reports that significant progress has been achieved in the exploration of cataract mechanisms and the development of new drugs in recent years, but substantial challenges remain in translating these discoveries into clinically applicable medications.
What is still missing is a drug that can reverse lens opacification rather than merely slow its progression. No pharmacological intervention has yet been shown in a controlled trial to restore transparency in a human cataractous lens. The basic mechanisms linking specific genetic mutations, such as p.F32I in GJA8, to the protein misbehaviour that causes opacity are not fully understood, and no drug candidate has been designed to correct that specific molecular defect. Money for large-scale, long-term clinical trials of any candidate compound, and a reliable method to stratify patients by cataract subtype or genetic cause, are still absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ophthalmic Epidemiology · 1997 · 11 citations
Associations between lens features assessed in the Oxford Clinical Cataract Classification and Grading System
AbstractPURPOSE: To study the associations between eleven lens features graded according to the Oxford Clinical Cataract Classification and Grading System (OCCCGS). METHOD: 560 subjects taking part in the Melton Eye Study had their lenses graded according to the OCCCGS by one of two examiners. Associations between features were examined using log-linear models for categorised grades. Adjustment was made for age, sex and grader. RESULTS: Within subjects, the two nuclear features, white nuclear scatter and brunescence, are closely related with one another, as are coronary flakes and focal-dots, but these two groupings are negatively associated. Cortical spoke, fibrefolds and waterclefts are all associated with one another and this group is positively associated with coronary flakes and focal-dots. Posterior subcapsular and anterior subcapsular opacity are associated with one another and with cortical spokes. A within-eye analysis gives similar results. CONCLUSION: These associations may be important in defining cataract subtypes and in identifying minor features that indicate early cataract development.
International Journal of Ophthalmology · 2016 · 5 citations · open access
A novel mutation of p.F32I in GJA8 in human dominant congenital cataracts
AbstractAIM: To identify a causative mutation in a three-generation family with autosomal dominant congenital total cataract and dissect the molecular consequence of the identified mutation. METHODS: Clinical and ophthalmological examinations were performed on the affected and unaffected family members. Mutation were screened in recruited family members by polymerase chain reaction (PCR) of the two reported genes (CRYAA and GJA8) which were linked to human total cataracts and direct sequencing of the PCR product. The molecular consequences of the identified mutation was dissected. The plasmids carrying wild-type and mutant mouse ORF of Gja8, coding for connexin 50 (Cx50), were generated and ectopic expressed in 293 cells. Recombinant protein expression and cellular localization of recombinated Cx50 were assessed by confocal microscopy. RESULTS: Clinical and ophthalmological examinations were performed on the affected and unaffected family members. Mutation were screened in recruited family members by PCR of the two reported genes (CRYAA and GJA8) which were linked to human total cataracts and direct sequencing of the PCR product. The molecular consequences of the identified mutation was dissected. The plasmids carrying wild-type and mutant mouse ORF of Gja8, coding for Cx50, were generated and ectopic expressed in 293 cells. Recombinant protein expression and cellular localization of recombinated Cx50 were assessed by confocal microscopy. CONCLUSION: This study has identified a novel cataract mutation in GJA8, which adds a novel mutation to the existing spectrum of Cx50 mutations with cataract. The molecular consequences of p.F32I mutation in GJA8 exclude instability and the mislocalization of mutant Cx50 protein.
DOAJ (DOAJ: Directory of Open Access Journals) · 2025 · 0 citations · open access
Pharmacological treatment and research progress of cataracts
AbstractCataracts remain the leading cause of blindness globally. They manifest as lens opacification triggered by various factors, leading to blurred vision. In severe cases, patients may eventually lose their vision entirely. There are many types of cataracts, and their pathogenesis has not been fully clarified. Currently, oxidative stress is widely acknowledged as the primary influencing factor. Pharmacological intervention remains a significant clinical challenge in cataract management. At present, there are no drugs on the market capable of truly reversing cataracts; existing medications can only alleviate the progression of the condition to a certain extent. Surgical treatment remains the only effective approach at this stage. However, economic limitations and the risks of postoperative complications hinder its accessibility for certain patient groups. The treatment of cataracts has consistently been a research hotspot in the field of ophthalmology. Current research mainly centers on two strategic approaches: optimizing surgical techniques alongside improved perioperative pharmaceutical regimens to minimize complications, and conducting basic researches on disease mechanisms to facilitate drug discovery. Effective drug treatment has long been a major gap in current clinical treatment. In recent years, significant progress has been achieved in the exploration of cataract mechanisms and the development of new drugs. Despite the remarkable advancements in uncovering cataract pathogenesis and identifying novel therapeutic targets in recent years, substantial challenges remain in translating these discoveries into clinically applicable medications. This article reviews the progress in mechanism research, the current state of pharmacological interventions, and the clinical research developments of several promising cataract drugs, aiming to provide the latest reference for the research and development of new cataract drugs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
